YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease - sprookjes - yvandenbroek - TriplyDB

YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease

YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease

http://www.wikidata.org/entity/Q34447497

about

Cerebrospinal fluid biomarkers of Alzheimer’s disease Revolutionizing Alzheimer's disease and clinical trials through biomarkers Perspectives for Monocyte/Macrophage-Based Diagnostics of Chronic Inflammation Expanding the Repertoire of Biomarkers for Alzheimer's Disease: Targeted and Non-targeted Approaches Fluid Biomarkers in Clinical Trials of Alzheimer's Disease Therapeutics Approaches for targeted proteomics and its potential applications in neuroscience Body fluid biomarkers in Alzheimer's disease Meta-Review of CSF Core Biomarkers in Alzheimer's Disease: The State-of-the-Art after the New Revised Diagnostic Criteria Recent advances in quantitative neuroproteomics Biomarkers in dementia: clinical utility and new directions IVIg protects the 3xTg-AD mouse model of Alzheimer’s disease from memory deficit and Aβ pathology Top-down proteomics with mass spectrometry imaging: a pilot study towards discovery of biomarkers for neurodevelopmental disorders A Subset of Cerebrospinal Fluid Proteins from a Multi-Analyte Panel Associated with Brain Atrophy, Disease Classification and Prediction in Alzheimer's Disease Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosis Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's disease Update on the core and developing cerebrospinal fluid biomarkers for Alzheimer disease.Biomarkers in the Diagnosis and Prognosis of Alzheimer's Disease.Efavirenz promotes β-secretase expression and increased Aβ1-40,42 via oxidative stress and reduced microglial phagocytosis: implications for HIV associated neurocognitive disorders (HAND).Phosphorylated tau-Aβ42 ratio as a continuous trait for biomarker discovery for early-stage Alzheimer's disease in multiplex immunoassay panels of cerebrospinal fluid.Recent Progress in Alzheimer's Disease Research, Part 3: Diagnosis and Treatment.The use of biophysical proteomic techniques in advancing our understanding of diseases.Biochemical markers in vascular cognitive impairment associated with subcortical small vessel disease - A consensus report Identification of longitudinally dynamic biomarkers in Alzheimer's disease cerebrospinal fluid by targeted proteomics.YKL-40 (Chitinase 3-like I) is expressed in a subset of astrocytes in Alzheimer's disease and other tauopathies.Profiling the genes affected by pathogenic TDP-43 in astrocytes Cerebrospinal Fluid Aβ43 Is Reduced in Early-Onset Compared to Late-Onset Alzheimer's Disease, But Has Similar Diagnostic Accuracy to Aβ42.Increased Levels of Chitotriosidase and YKL-40 in Cerebrospinal Fluid from Patients with Alzheimer's Disease.Biomarkers of Alzheimer's disease risk in peripheral tissues; focus on buccal cells.Serum YKL-40 levels correlate with infarct volume, stroke severity, and functional outcome in acute ischemic stroke patients The mediational effects of FDG hypometabolism on the association between cerebrospinal fluid biomarkers and neurocognitive function Quantitative label-free proteomics for discovery of biomarkers in cerebrospinal fluid: assessment of technical and inter-individual variation.Emerging biomarkers in cognition.Comparison of analytical platforms for cerebrospinal fluid measures of β-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology RelB/p50 complexes regulate cytokine-induced YKL-40 expression Biomarkers for microglial activation in Alzheimer's disease.Diverse inflammatory responses in transgenic mouse models of Alzheimer's disease and the effect of immunotherapy on these responses.The Inflammatory Marker YKL-40 Is Elevated in Cerebrospinal Fluid from Patients with Alzheimer's but Not Parkinson's Disease or Dementia with Lewy Bodies.Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age.Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer's disease in a memory clinic cohort.Alzheimer Disease Cerebrospinal Fluid Biomarkers Moderate Baseline Differences and Predict Longitudinal Change in Attentional Control and Episodic Memory Composites in the Adult Children Study.

P2860

Q22252572-0AF8A421-5525-4D6C-B551-7960720CFC78 Q26744882-38151E33-ECD2-47F3-AEE0-9D970D5D7BE4 Q26745913-04281E85-67E4-4BEA-9886-F73F95F90D1E Q26770708-AC22D40D-0971-4658-9980-4CCC35F9A71E Q26784569-C7DA7B67-4435-4AE8-B9E3-53A9AD656036 Q26786427-055F0658-A394-49CB-84A3-02BBFB5527EE Q26830098-276DD498-5045-4055-9AF0-41915025CAAA Q26864063-DA3D869D-42AB-4E15-A1ED-A19EF2AAEDDB Q27000073-1D71EE91-46E7-4A6F-92AD-9DD501B98B03 Q27007086-3EBC6F4B-8C03-40AB-90B3-0A78406235DF Q27497796-602F411D-9B45-49E3-AC6A-9A71F096588C Q28542079-399EEB0A-3BB1-4A3E-93EE-D0D2294CB286 Q28547333-EC345704-0DB1-4C80-8647-47653BF64658 Q28740917-B06ACDE9-6C81-4F64-AE56-FD3706B3A86F Q28743561-164193B0-DAD3-4B85-8C86-89057910BFEB Q30845482-A7EF129C-32A8-4D61-A987-6805EE7F9F4C Q30871982-78073402-7913-4F33-B539-EA892D2F6428 Q31159582-4774C3F8-D743-41BF-84D9-E51B546F1D5A Q33554802-6C87AB56-E6C5-4990-AA21-44F32D8D390A Q33556068-8A1A6609-8BDC-4830-8126-4CD7A98ED291 Q33639590-44303953-453A-411B-8E1C-F198101FA590 Q33721681-EE552279-F1D4-4DBC-8F3F-E86415EDA131 Q33769278-BABC0482-E07E-4022-B887-261679BA47A7 Q33784904-4D10A90A-6546-4395-AAF3-74BBB69985FC Q33789456-F6D68623-5150-4E38-AEC3-8A5C7CAF34F9 Q33843517-2D068326-037B-4BB2-9D81-C3EEA0D9EB73 Q34181135-6D111C3C-0AA5-47EA-9428-EAC5ABECC58C Q34201730-4B6BAB14-71D2-402E-90B2-37222927C705 Q34525564-0156895E-FE16-4E43-8E9C-5DA3D114CEB9 Q34674417-4A4E9C4D-F56B-4A87-9C38-1C8352557500 Q34735454-970B5E64-0D57-4636-9677-D93EE3EEE16B Q35008258-A612B1A3-392C-4DAF-A293-8480AED73D34 Q35161042-BC665646-50FA-4091-ACFE-47ACB7C47A67 Q35164695-4691A594-ABA3-47DB-8EEE-2B5AEF4F9EE5 Q35504167-3424FDCF-B11B-45A3-A14B-A0983A1B49D5 Q35581445-D71E94CB-B34B-43CC-99A9-9CA4AE700E44 Q35745168-43D884D0-A5F1-4EEA-8A2C-F1091BE36787 Q36062391-82C8EB26-5471-4F84-A188-F6F8A87B9F23 Q36071742-4B6E4B46-58AD-4CC3-8E41-F06C62C48A81 Q36175421-2EA924CD-7487-4132-9AA1-DD2D2BA7D1E2

P2860

YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease

http://www.wikidata.org/entity/Q34447497

description

2010 nî lūn-bûn

@nan

2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease

@ast

YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease

@en

YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease

@nl

type

label

YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease

@ast

YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease

@en

YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease

@nl

prefLabel

YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease

@ast

YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease

@en

YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease

@nl

P1433

Q34447497-5847DC35-79C0-4C38-80C6-9CBCFC8CB66B

P1476

Q34447497-21B36986-AC80-40BD-9E84-A450A9EF270C

P2093

Q34447497-3E2C30E9-B3C5-489D-8A12-E90678A9A6CE

Q34447497-418F4959-7FAA-447F-9B4D-6688B90B2F18

Q34447497-47C22ED5-9310-4761-9BE0-A9B5614737BA

Q34447497-5B37CD01-24A7-47EC-A942-2B035CB82E0A

Q34447497-60FCDC1C-A073-46DB-BFE7-10E6586905A9

Q34447497-6DB3212B-246F-4776-826E-7C31F1670861

Q34447497-70A3F446-4B48-4E1B-B6DB-9380EA49905D

Q34447497-8F761AAF-05DF-4774-9EB4-EAB209E67397

Q34447497-A2A755CE-74D6-4D7F-A46F-01C214C250C1

Q34447497-ACB74939-B9E8-418A-B9D5-82AF82BB0AD6

P2860

Q34447497-02F374A1-3EB1-49BC-9223-193A011BA994

Q34447497-0E493CC5-AC24-4601-9A00-B7DA1ACDDD23

Q34447497-19336E7F-8358-445A-9461-7A33ADEB72FD

Q34447497-205E6D17-75C1-4641-8351-424D0F6E5268

Q34447497-2260D3F6-F353-49F9-812D-3E3FAED3C57B

Q34447497-2696B0EA-B188-4747-8C74-222EF78D1B55

Q34447497-2ABB804C-BC12-4A58-8F43-0B0EF9BB3586

Q34447497-2DB7F02C-8C97-4191-8A61-E60349BDAB24

Q34447497-2F258CAE-3226-40D9-BCAC-78746ECA98D1

Q34447497-342DF136-B86B-47E5-80D0-1A27A93C94EF

P304

Q34447497-BCA60ABD-AFB8-4B8A-BE89-7BEFAFA4149A

P31

Q34447497-CF98EA3C-605D-40B3-BBDB-F3BFF0C5EAC5

P356

Q34447497-A89D3901-50AE-4608-A543-118825491BF4

P407

Q34447497-F4678DF6-479B-449C-86BA-4EADE6CFE07A

P433

Q34447497-A718F0EB-73C9-49F1-9152-7BAA92D60099

P478

Q34447497-8066B195-4471-40E1-9AF4-A12165B3B235

P50

Q34447497-03212247-F25D-4D3D-B268-2C9388F1FAE5

Q34447497-363F92C5-4A73-44E3-8D3F-41C2BB55DCAB

Q34447497-42EE7C43-7285-4B69-82D1-4887170DDFEA

Q34447497-E0ADF95B-B428-4A89-A1F3-6D822A964574

P577

Q34447497-F0F6CF8E-B0DD-4728-A7F3-29BFD6615CFB

P5875

Q34447497-D356C0EA-E797-4F6D-B565-E89EE39A2AAC

P698

Q34447497-1D1E8929-08D9-47AC-8EF5-895E698536A0

P921

Q34447497-B8E17242-AD68-4D6F-A47A-1DF276DF52FD

Q34447497-C912C2F7-4354-4A64-9955-FBEE86EDD06B

P932

Q34447497-18A15AB0-C232-4C89-818D-FA5474354F2B

P356

J.BIOPSYCH.2010.08.025

P1433

Biological Psychiatry

P1476

YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease

@en

P2093

Catherine M Roe

http://www.w3.org/2001/XMLSchema#string

Chengjie Xiong

http://www.w3.org/2001/XMLSchema#string

Christopher M Clark

http://www.w3.org/2001/XMLSchema#string

Deborah Carter

http://www.w3.org/2001/XMLSchema#string

Douglas R Galasko

http://www.w3.org/2001/XMLSchema#string

Elaine R Peskind

http://www.w3.org/2001/XMLSchema#string

Ge Li

http://www.w3.org/2001/XMLSchema#string

Gina D'Angelo

http://www.w3.org/2001/XMLSchema#string

James P Malone

http://www.w3.org/2001/XMLSchema#string

Joseph F Quinn

http://www.w3.org/2001/XMLSchema#string

P2860

Neurons in the white matter of the adult human neocortex

Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family

Inflammatory cytokines induce production of CHI3L1 by articular chondrocytes

YKL-40 is elevated in cerebrospinal fluid from patients with purulent meningitis

The chitinase 3-like protein human cartilage glycoprotein 39 (HC-gp39) stimulates proliferation of human connective-tissue cells and activates both extracellular signal-regulated kinase- and protein kinase B-mediated signalling pathways

Biomarkers of Alzheimer's disease

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

Inflammation and Alzheimer's disease

gp38k (CHI3L1) is a novel adhesion and migration factor for vascular cells

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B

P304

903-912

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.BIOPSYCH.2010.08.025

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

68

http://www.w3.org/2001/XMLSchema#string

P50

David M. Holtzman

P577

2010-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

47634343

http://www.w3.org/2001/XMLSchema#string

P698

21035623

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

P932

3011944

http://www.w3.org/2001/XMLSchema#string